Gys1 Antisense Therapy Prevents Disease-Driving Aggregates and Epileptiform Discharges in a Lafora Disease Mouse Model
Authors:
Open Access
- 12 September 2023
- journal article
- research article
- Published by Elsevier in Neurotherapeutics
- Vol. 20 (6) , 1808-1819
Abstract
No abstract availableKeywords
Funding Information
- Ionis Pharmaceuticals
This publication has 83 references indexed in Scilit:
- Deleterious effects of neuronal accumulation of glycogen in flies and miceEMBO Molecular Medicine, 2012
- Neurology of inherited glycosylation disordersThe Lancet Neurology, 2012
- Neurodegeneration and functional impairments associated with glycogen synthase accumulation in a mouse model of Lafora diseaseEMBO Molecular Medicine, 2011
- PTG Depletion Removes Lafora Bodies and Rescues the Fatal Epilepsy of Lafora DiseasePLOS Genetics, 2011
- Phosphate Incorporation during Glycogen Synthesis and Lafora DiseaseCell Metabolism, 2011
- Genetic Depletion of the Malin E3 Ubiquitin Ligase in Mice Leads to Lafora Bodies and the Accumulation of Insoluble LaforinJournal of Biological Chemistry, 2010
- Abnormal Metabolism of Glycogen Phosphate as a Cause for Lafora DiseaseJournal of Biological Chemistry, 2008
- Malin Decreases Glycogen Accumulation by Promoting the Degradation of Protein Targeting to Glycogen (PTG)Journal of Biological Chemistry, 2008
- Laforin is a glycogen phosphatase, deficiency of which leads to elevated phosphorylation of glycogen in vivoProceedings of the National Academy of Sciences, 2007
- Laforin, a Dual Specificity Phosphatase That Dephosphorylates Complex CarbohydratesJournal of Biological Chemistry, 2006